<DOC>
	<DOCNO>NCT00150267</DOCNO>
	<brief_summary>To estimate frequency patient ocular/periorbital adverse event . To identify possible long-term adverse consequence increase iris pigmentation follow serious adverse event throughout study period .</brief_summary>
	<brief_title>A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Patients open angle glaucoma and/or ocular hypertension require reduction IOP insufficiently responsive topical betablockers Previous current treatment topical ophthalmic drug containing prostaglandin ; condition treatment betablocking agent , timolol , contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
</DOC>